ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · Real-Time Price · USD
0.386
-0.017 (-4.22%)
Feb 21, 2025, 4:00 PM EST - Market closed
-4.22%
Market Cap 12.95M
Revenue (ttm) 17.27M
Net Income (ttm) -20.02M
Shares Out 33.53M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 842,285
Open 0.401
Previous Close 0.403
Day's Range 0.373 - 0.411
52-Week Range 0.325 - 2.430
Beta 0.20
Analysts Strong Buy
Price Target 5.00 (+1,195.0%)
Earnings Date Mar 13, 2025

About IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving industry challenges. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibod... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 3, 2017
Employees 101
Stock Exchange NASDAQ
Ticker Symbol IPA
Full Company Profile

Financial Performance

In 2024, ImmunoPrecise Antibodies's revenue was 24.52 million, an increase of 18.65% compared to the previous year's 20.67 million. Losses were -27.18 million, 2.32% more than in 2023.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 1,195.00% from the latest price.

Price Target
$5.0
(1,195.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced tha...

2 days ago - Business Wire

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA” or the “Company”) (NASDAQ: IPA), a leader in AI-driven antibody discovery and development, today announced the success...

26 days ago - Business Wire

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhanc...

4 weeks ago - Business Wire

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to t...

5 weeks ago - Business Wire

IPA Announces Resignation of Chief Financial Officer

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective J...

7 weeks ago - Business Wire

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

SANTA MARIA, Calif.--(BUSINESS WIRE)-- #apartmentinvestments--$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors.

Other symbols: MMI
7 weeks ago - Business Wire

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pl...

2 months ago - Business Wire

IPA to Present at The Microcap Conference 2025

VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced ...

2 months ago - Accesswire

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2025 Earnings Conference Call December 10, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Sw...

2 months ago - Seeking Alpha

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today repor...

2 months ago - Business Wire

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today...

2 months ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today...

2 months ago - Business Wire

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a signifi...

3 months ago - Business Wire

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces t...

3 months ago - Business Wire

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces i...

4 months ago - Business Wire

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today annou...

4 months ago - Business Wire

Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District

LOS ANGELES--(BUSINESS WIRE)-- #apartmentbrokers--Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District.

Other symbols: MMI
4 months ago - Business Wire

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today celeb...

4 months ago - Business Wire

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

VICTORIA, British Columbia & ZHUHAI, China--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology comp...

5 months ago - Business Wire

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an...

5 months ago - Business Wire

ImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2025 Earnings Conference Call September 16, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants S...

5 months ago - Seeking Alpha

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology...

5 months ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and tech...

5 months ago - Business Wire

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th ...

6 months ago - Business Wire

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company, announced today that the Company r...

6 months ago - Business Wire